The Tohoku journal of experimental medicine
-
Tohoku J. Exp. Med. · Feb 2018
Retraction Of PublicationRetraction: Nucleophagy in Human Disease: Beyond the Physiological Role. [Tohoku J. Exp. Med., 2018, 244 (1), 75-81. doi: 10.1620/tjem.244.75. Review.].
Retracted Review article: Nucleophagy in Human Disease: Beyond the Physiological Role. [Tohoku J. Exp. Med., 2018, 244 (1), 75-81. doi: 10.1620/tjem.244.75.] The above Review article was published online on January 27, 2018. ⋯ We also hope that the publication of the plagiarized Review article will not trouble Dr. Nian Fu and Prof. Linxi Chen too much.
-
Tohoku J. Exp. Med. · Aug 2017
Retraction Of PublicationRetraction: Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression.
We reported "Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression" in Tohoku J. Exp. ⋯ After publication of the paper, we have become aware of the ethical violation in collecting the samples from some patients. We therefore wish to retract the paper and apologize for any inconvenience caused by the retraction.
-
Tohoku J. Exp. Med. · Jan 2017
Retracted PublicationTranscription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression.
Osteosarcoma is a malignant bone cancer that mainly affects children. SOX9 plays a key role in bone formation and osteosarcoma, and Claudin-8 (CLDN8), a tight junction protein, contributes to proliferation of osteosarcoma cells. The aim of this study was to investigate the relationship between SOX9 and CLDN8 in osteosarcoma. ⋯ The transient luciferase-reporter assays suggest that SOX9 may inhibit the promoter activity of the CLDN8 gene in osteosarcoma cells. In conclusion, we provide the evidence demonstrating that SOX9 may promote cell growth by repressing the expression of CLDN8. Thus, SOX9 may be a therapeutic target for osteosarcoma.